Source: Julian Wan/Unsplash

• We all want to go back to normal
• A COVID vaccine might help us get there
• Lots of COVID vaccines are under development
• Deployment will be complex
• Simulation models can help in deployment decisions

• Lots (>100?) vaccine candidates under consideration
• Around 50 in human trials
• Around 10 in efficacy (phase 3) trials

https://vac-lshtm.shinyapps.io/ncov_vaccine_landscape/

https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html

• Pfizer/BioNTech, Moderna, AstraZeneca/U Oxford, Johnson & Johnson/Janssen, Novavax
• All in phase 3 trials, data from phase I/II looked promising.

https://doi.org/10.1038/s41586-020-2814-7

• Different technologies (RNA, DNA, subunit, inactivated, etc.)
• Different dosing (1 or 2)
• Different logistics (e.g. cold chain)
• Different efficacies (TBD)
• Different target groups (children, adults, elderly, etc.)

https://bit.ly/2TeB8q8

• Vaccine companies seek FDA approval.
• FDA reviews and approves, possibly giving emergency use authorization (EUA).
• Advisory Committee on Immunization Practices (ACIP) makes recommendations.
• State/Federal/Private Sector coordination for deployment.

https://www.rpc.senate.gov/policy-papers/distributing-covid-19-vaccines

National Academies of Sciences, Engineering, and Medicine “Framework for Equitable Allocation of COVID-19 Vaccine”

https://doi.org/10.17226/25917

• Figuring out how to deploy vaccines in the most efficient way is not easy.
• Simulation models can help guide decisions of vaccination campaigns.

https://bit.ly/2T7nuFw

• Collaborators: Molly E. Gallagher, Andrew J. Sieben, Kristin N. Nelson, Alicia N. M. Kraay, Ben Lopman, Katia Koelle
• Funding: NIH
• Slides: https://www.andreashandel.com/talk/
• Contact: https://www.andreashandel.com/, @andreashandel